Exane Derivatives’s CATALENT, INC. CTLT Stock Holding History

Exane Derivatives’s Portfolio CTLT Stock Details CTLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-246,886	Closed	-$6.65M	–	692
2016 Q4	$6.65M	Buy	246,886 +75,762	+44%	+$1.88M	1.31%	10
2016 Q3	$4.42M	Buy	171,124 +115,963	+210%	+$2.88M	0.66%	43
2016 Q2	$1.27M	Buy	+55,161	New	+$1.45M	0.21%	73

Other funds holding CTLT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Exane Derivatives's CTLT Position: Q1 2017 in Review

Exane Derivatives sold out of CATALENT, INC. (CTLT) in Q1 2017, closing a stake of 246,886 shares — an estimated $6.65M sold.

Exane Derivatives first reported a position in CTLT in Q2 2016 and held it in 3 quarters. The position peaked at $6.65M in Q4 2016. 209 funds tracked by Wall St. Rank hold CTLT as of Q1 2017.

Exane Derivatives reported no remaining CATALENT, INC. position as of Q1 2017 after selling out during the quarter.
Exane Derivatives sold 246,886 CATALENT, INC. shares in Q1 2017, an estimated $6.65M.
Exane Derivatives first reported a position in CATALENT, INC. in Q2 2016 and held it in 3 quarters.
Exane Derivatives's CATALENT, INC. position peaked at $6.65M in Q4 2016.
209 funds tracked by Wall St. Rank held CATALENT, INC. as of Q1 2017.

Based on Exane Derivatives's 13F filing for Q1 2017, filed 28 Apr 2017.